Ropinirole and pramipexole: Difference between revisions
Jump to navigation
Jump to search
NCLEX nursing pharmacology monographs — batch import |
Add medication infobox (Drugbox) to monographs |
||
| Line 1: | Line 1: | ||
{{Drugbox | |||
| name = Ropinirole and pramipexole | |||
| brand = Requip, Mirapex | |||
| therapeutic = Antiparkinson, restless legs agent | |||
| pharmacologic = Nonergot dopamine agonists | |||
| onset = Effect over titration; ER once daily. | |||
| halflife = Ropinirole about 6 hours, pramipexole about 8 to 12 hours; level not routine. | |||
| routes = PO (oral) | |||
| highalert = No | |||
| blackbox = None | |||
| antidote = None. | |||
| pregnancy = Use only if essential. | |||
}} | |||
<div style="border-left:4px solid #3f6f5b;background:#f3f6f4;padding:8px 12px;margin-bottom:12px;font-size:0.95em;"> | <div style="border-left:4px solid #3f6f5b;background:#f3f6f4;padding:8px 12px;margin-bottom:12px;font-size:0.95em;"> | ||
''Nursing pharmacology study reference (NCLEX-style monograph). Numeric values are standard teaching ranges for study and '''must be verified against current manufacturer labeling before clinical use'''. This is educational content, not prescribing guidance.'' | ''Nursing pharmacology study reference (NCLEX-style monograph). Numeric values are standard teaching ranges for study and '''must be verified against current manufacturer labeling before clinical use'''. This is educational content, not prescribing guidance.'' | ||
Latest revision as of 16:09, 17 June 2026
| Drug monograph · NCLEX study reference | |
| Trade names | Requip, Mirapex |
|---|---|
| Therapeutic class | Antiparkinson, restless legs agent |
| Pharmacologic class | Nonergot dopamine agonists |
| Onset / peak / duration | Effect over titration; ER once daily. |
| Half-life / level | Ropinirole about 6 hours, pramipexole about 8 to 12 hours; level not routine. |
| Routes | PO (oral) |
| High-alert (ISMP) | No |
| Black box warning | None |
| Antidote / reversal | None. |
| Pregnancy / lactation | Use only if essential. |
Nursing pharmacology study reference (NCLEX-style monograph). Numeric values are standard teaching ranges for study and must be verified against current manufacturer labeling before clinical use. This is educational content, not prescribing guidance.
Ropinirole and pramipexole (brand names Requip, Mirapex) — Antiparkinson, restless legs agent; Nonergot dopamine agonists.
Identification
- Therapeutic class: Antiparkinson, restless legs agent.
- Pharmacologic class: Nonergot dopamine agonists.
Pharmacology
- Mechanism of action: Directly stimulate dopamine receptors.
- Onset / peak / duration: Effect over titration; ER once daily.
- Half-life / therapeutic level: Ropinirole about 6 hours, pramipexole about 8 to 12 hours; level not routine.
Clinical use
- Indications: Parkinson disease, restless legs syndrome.
- Usual dose, route, frequency: Titrated PO; pramipexole reduced in renal impairment.
- Maximum dose / adjustments: Titrate slowly; taper to stop.
Safety
- Contraindications: Hypersensitivity.
- Black box warning: None.
- Interactions: Dopamine antagonists oppose effect, CNS depressants.
- Pregnancy / lactation: Use only if essential.
- High-alert: No.
Adverse effects
- Common side effects: Nausea, dizziness, somnolence.
- Serious effects to report: Sudden sleep attacks, impulse-control disorders, orthostatic hypotension, hallucinations.
- Antidote / reversal: None.
Nursing process
- Assessment before administration: Motor and mental status, blood pressure, renal function (pramipexole).
- Interventions during therapy: Caution driving; screen for impulse behaviors.
- Monitor: Motor function, mood and behavior, blood pressure.
- Evaluation / expected outcome: Improved motor symptoms or restless legs.
Patient teaching
- Patient teaching: Report falling asleep suddenly or new compulsive behaviors.
- Notify provider if: Sleep attacks, gambling or other impulses, hallucinations.
- Administration tips: Titrate slowly; taper to discontinue.